A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Study Summary

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.

Conditions

Acute Leukemias Acute Myeloid Leukemia Acute Lymphoblastic Leukemia

Interventions / Drugs

Bleximenib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment400 participants

Primary Completion—

Lead SponsorJanssen Research & Development, LLC

Data Retrieved2026-04-11 02:55:31.550765+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.